Details for New Drug Application (NDA): 020692
✉ Email this page to a colleague
The generic ingredient in SEREVENT is salmeterol xinafoate. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the salmeterol xinafoate profile page.
Summary for 020692
Tradename: | SEREVENT |
Applicant: | Glaxosmithkline |
Ingredient: | salmeterol xinafoate |
Patents: | 0 |
Pharmacology for NDA: 020692
Mechanism of Action | Adrenergic beta2-Agonists |
Medical Subject Heading (MeSH) Categories for 020692
Suppliers and Packaging for NDA: 020692
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
SEREVENT | salmeterol xinafoate | POWDER;INHALATION | 020692 | NDA | GlaxoSmithKline LLC | 0173-0521 | 0173-0521-00 | 1 INHALER in 1 CARTON (0173-0521-00) / 60 POWDER, METERED in 1 INHALER |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INHALATION | Strength | EQ 0.05MG BASE/INH | ||||
Approval Date: | Sep 19, 1997 | TE: | RLD: | Yes |
Expired US Patents for NDA 020692
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline | SEREVENT | salmeterol xinafoate | POWDER;INHALATION | 020692-001 | Sep 19, 1997 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline | SEREVENT | salmeterol xinafoate | POWDER;INHALATION | 020692-001 | Sep 19, 1997 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline | SEREVENT | salmeterol xinafoate | POWDER;INHALATION | 020692-001 | Sep 19, 1997 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline | SEREVENT | salmeterol xinafoate | POWDER;INHALATION | 020692-001 | Sep 19, 1997 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline | SEREVENT | salmeterol xinafoate | POWDER;INHALATION | 020692-001 | Sep 19, 1997 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription